Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations

The Supreme Court of Canada has dismissed appeals brought by drug manufacturers challenging the constitutionality of the federal government's authority to negotiate and set prices for drugs covered under the Canada Drug Agency (CDA) program. The decision upholds the government’s right to regulate drug pricing as part of its broader powers in healthcare. In a joint statement, the drug manufacturers argued that provincial governments have exclusive jurisdiction over health care services, including the negotiation of drug prices. However, the Supreme Court ruled against their claims, stating tha…